Following the receipt of Orphan Drug Designation for their lead product, NRL-1 (intranasal diazepam), Neurelis, Inc. (“Neurelis”) today announced the receipt of guidance from the FDA for the final clinical trial requirements necessary for approval of NRL-1. NRL-1 is being developed for pediatric, adolescent, and adult epilepsy patients who experience Acute Repetitive Seizures. Neurelis has […]
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are about to enter a site containing information on Medical Affairs and Research that is intended for US healthcare professionals only. Please confirm you are a healthcare professional and you wish to proceed to the HCP-only site.